Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ST 503

Next Previous
Drug Profile

ST 503

Alternative Names: ST-503

Latest Information Update: 04 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sangamo Therapeutics
  • Class Analgesics; Gene therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Gene transference; NAV1.7 voltage gated sodium channel expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Neuropathic pain

Most Recent Events

  • 02 Dec 2025 ST 503 receives Fast Track designation for Neuropathic pain [Intrathecal] in USA
  • 02 Dec 2025 Pharmacodynamics data from a preclinical study in Neuropathic pain released by Sangamo Therapeutics
  • 28 Oct 2025 Phase-I/II clinical trials in Neuropathic pain in USA (Intrathecal) (Sangamo Therapeutics Pipeline, August 2025) (NCT06980948)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top